Tesaro combo leads to partial responses in NSCLC patients

Tesaro Inc. (NASDAQ:TSRO) reported data from the open-label Phase I AMBER trial showing that a combination of TSR-022 and TSR-042 led to four confirmed partial responses and 11 cases of stable disease among 31 evaluable non-small cell lung cancer patients who progressed following anti-PD-1 treatment. The company said all four of the responses occurred in PD-L1-positive patients.

TSR-022 is an anti-TIM3 (T cell immunoglobulin and mucin domain 3; HAVCR2) mAb and TSR-042 is an anti-PD-1 mAb. Tesaro presented the data at the Society for Immunotherapy of Cancer meeting in Washington...